There is one clinical trial.

Clinical Trials

1 Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19

The most severe manifestations of COVID-19 include respiratory failure, coagulation problems, and death. Inflammation and blood clotting are believed to play an important role in these manifestations. Research in humans has shown that dipyridamole can reduce blood clotting. This research study is being conducted to learn whether 14 days of treatment with dipyridamole will reduce excessive blood clotting in COVID-19. This study will enroll participants with confirmed coronavirus (SARS-CoV)-2 infection that are admitted. Eligible participants will be randomized to receive dipyridamole or placebo for 14 days in the hospital. In addition, data will be collected from the medical record, and there will also be blood draws during the hospitalization.

NCT04391179 COVID Corona Virus Infection Covid-19 SARS-CoV-2 Infection Drug: Dipyridamole 100 Milligram(mg) Drug: Placebo oral tablet

MeSH:Infection Communicable Diseases Coronavirus Infections Severe Acute Respiratory Syndrome

No related HPO nodes (Using clinical trials)